Together, we realize the full potential of life sciences to impact lives.
Life sciences is entering its Advanced Intelligence era.
PLG pairs deep human expertise with intelligent automation - so every decision stays fast, valuable, and owned by a senior expert, from discovery to patient impact.
.png?width=20&height=17&name=Vector%20(2).png){kind=small}
Breakthroughs don't change lives in the lab.
They change lives when science reaches the people it's made for.
That shift needs more than intelligence, it needs judgment.
Advanced Intelligence for Life Sciences means human expertise, amplified by automation, accountable at every decision.
Read our Manifesto
~1,750 experts
Our Solutions
Bringing a product to market and sustaining its success requires integrated expertise across every stage of its lifecycle. Our solutions are structured around that journey, connecting capabilities across development, access, compliance, and innovation.
What's shaping access today
Two regulatory and commercial shifts reshaping European market access, and how PLG is already helping clients navigate them.
Joint Clinical Assessment (JCA)
EMA approval opens the market. A Joint Clinical Assessment fixes your comparators at EU level. We run regulatory strategy, JCA and national pricing as one coordinated programme.
Value-Added Medicines (VAM)
Turning incremental innovation - new formulations, delivery routes and combinations - into premium, defensible pricing across global markets.
Application sectors
We provide specialised regulatory and compliance expertise across the core pillars of the life sciences industry, ensuring safety and excellence at every scale.
- Biopharmaceutical drug development services
- Regulatory Affairs Services
- CMC & Quality: Pharma’s Pathway to Excellence
- Non-clinical and toxicology development
- Clinical development services
- Medical device and medtech services
- MDR & IVDR compliance
- Quality management systems
- Self-care product strategy
- Regulatory and compliance consulting
- Market access & reimbursement
Global Reach
Operating as a unified global network with specialised localised execution.
-
50+
Global offices
-
150+
Countries Covered
-
~1,750
Experts
-
10k+
Submissions/year
.png?width=1946&height=1081&name=PLG%20MAP-2026%20(1).png)
Where deep expertise meets exciting opportunities.
As part of PLG, you'll join our sector's most trusted advisor: one unified, high-performing team of Advanced Intelligence experts, across Regulatory Affairs, Quality, Safety, Clinical Development, Market Access, Engineering, and Digital & AI, as well as commercial and corporate support functions partnering with life sciences innovators to bring new medicines and technologies to patients, faster.
Expert Insights
Stay informed with the latest PLG news, industry insights, expert perspectives, and thought leadership shaping the future of life sciences and healthcare innovation.
Co-written by: Faiza Tahaout Key regulatory changes and practical implications for organisations involved in parallel importation, distribution, trade and repackaging.
Most Value-Added Medicines don't fail in the lab. They fail at the point where a regulator, an HTA body or a payer has to decide what the improvement is actually worth.
A new study by PLG Market Access experts, published in Global & Regional Health Technology Assessment, surveys European pharma leaders on how AI is being adopted in Market Access, what is holding it back, and where it is heading next. Artificial ...
Events & Webinars
View our most recent webinars below, covering topics from regulatory affairs to serialization.
EventsSeptember 24, 2026
Lean Lab 2026
May 26, 2026
Europe's HTA Shift Is Changing What "Launch Readiness" Means for Chinese Biopharma Companies
Webinars
Join PLG pulse
One monthly read to keep you informed on what matters in life sciences: expert perspectives, regulatory developments, upcoming events, webinars and more.
News & Press Releases
Stay up to date with PLG's latest news, press releases, and company milestones - from strategic partnerships to key achievements.
Co-written by: Faiza Tahaout Key regulatory changes and practical implications for organisations inv...
Annex 1 now comes with an official reading guide By Daniele Calzolari, Service Area Manager Manufact...
How risk-based assurance, AI governance and regulatory compliance are shaping the adoption of artifi...
The latest clarifications published in the Compl’Alim newsletter provide important guidance on the n...
One of the main challenges of the European Joint Clinical Assessment (JCA) does not lie in preparing...
Most Value-Added Medicines don't fail in the lab. They fail at the point where a regulator, an HTA b...
A sunscreen enquiry can start with a simple question about SPF and end in an adverse event, quality ...
On 29 September 2026, Lean Lab, the LifeBee format that has brought Life Sciences laboratory profess...
Two important regulatory developments published this month indicate meaningful progress for CBD as a...
More than 300 million people worldwide live with a rare disease. Yet despite remarkable scientific a...
Memberships & Associations
